

Amendments to the Claims

The following listing of claims will replace all prior versions, and listings, of claims in the application.

1-33. **(Cancelled)**

34. **(New)** A composition comprising dead *E. coli* containing therein at least one modified peanut allergen whose amino acid sequence differs from that of a wild-type peanut allergen that occurs in nature such that the modified peanut allergen has a reduced ability to bind to or cross-link IgE as compared with the wild-type peanut allergen.

35. **(New)** The composition of claim 34, wherein the wild-type peanut allergen is Ara h 1 (SEQ ID NO:1).

36. **(New)** The composition of claim 34, wherein the wild-type peanut allergen is Ara h 2 (SEQ ID NO:2).

37. **(New)** The composition of claim 34, wherein the wild-type peanut allergen is Ara h 3 (SEQ ID NO:3).

38. **(New)** The composition of claim 34, wherein the sequence of the modified peanut allergen differs from the sequence of the wild-type peanut allergen by one or more amino acid deletions, substitutions or additions within an IgE binding site of the wild-type peanut allergen.

39. **(New)** The composition of claim 38, wherein the sequence of the modified peanut allergen lacks a portion of the wild-type peanut allergen sequence, and wherein said portion includes an IgE binding site.

40. **(New)** The composition of claim 34, wherein the modified peanut allergen is located in the cytoplasm of the dead *E. coli*.

41. (New) The composition of claim 34, wherein the modified peanut allergen is located in the periplasm of the dead *E. coli*.

42. (New) The composition of claim 34, wherein the modified peanut allergen cannot be detected by antibody binding without disrupting the dead *E. coli*.